share_log

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Manting Erik

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Manting Erik

Transcode Therapeutics | 4：持股變動聲明-董事 Manting Erik
美股sec公告 ·  06/19 04:22
牛牛AI助理已提取核心訊息
Erik Manting, a key figure at Transcode Therapeutics, Inc. [RNAZ], has engaged in a transaction involving the company's stock on June 14, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. Consequently, the number of shares Manting holds after the transaction remains unknown.
Erik Manting, a key figure at Transcode Therapeutics, Inc. [RNAZ], has engaged in a transaction involving the company's stock on June 14, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. Consequently, the number of shares Manting holds after the transaction remains unknown.
2024年6月14日，Transcode Therapeutics, Inc. [RNAZ] 的關鍵人物 Erik Manting 進行了一筆涉及該公司股票的交易。公告中並未透露交易的具體細節，包括股份數量、股票性質、交易價格和股票總價值。此外，交易類型和狀態也未提供。因此，Manting 在交易後所持有的股份數目仍然未知。
2024年6月14日，Transcode Therapeutics, Inc. [RNAZ] 的關鍵人物 Erik Manting 進行了一筆涉及該公司股票的交易。公告中並未透露交易的具體細節，包括股份數量、股票性質、交易價格和股票總價值。此外，交易類型和狀態也未提供。因此，Manting 在交易後所持有的股份數目仍然未知。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。